Drug Resistance and Persistence in Tuberculosis

结核病的耐药性和持久性

• 批准号: 8255025
• 负责人: James Wavell Aiken
• 金额: $ 0.6万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8255025
• 关键词: Address; Bacteria; Biology; Cessation of life; Clinical; Collaborations; Country; Developed Countries; Development; Drug Delivery Systems; Drug Resistant Tuberculosis; Drug resistance; Drug resistance in tuberculosis; Drug-sensitive; Extreme drug resistant tuberculosis; Fostering; Genetic; Knowledge; Laboratories; Lead; Low Prevalence; Mentors; Methods; Multidrug-Resistant Tuberculosis; Mycobacterium tuberculosis; Outcome; Patients; Pharmaceutical Preparations; Population; Predisposition; Public Health; Regimen; Reporting; Request for Applications; Research; Research Personnel; Resistance; Scientific Advances and Accomplishments; Scientist; Students; Testing; Training; Treatment Protocols; Tuberculosis; Uganda; Work; World Health Organization; compliance behavior; drug candidate; drug discovery; drug sensitivity; improved; innovation; meetings; mycobacterial; novel; point of care; public health priorities; skills; symposium; treatment duration; tuberculosis drugs; tuberculosis treatment

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled Drug Resistance and Persistence in Tuberculosis, organized by Ann M. Ginsberg and John D. McKinney, which will be held in Kampala, Uganda from May 13-18, 2012. According to the World Health Organization, over 25% of new tuberculosis cases in some sub-national regions are MDR-TB and, as of March 2010, 58 countries had reported XDR-TB (TB resistant to the major classes of both first- and second-line drugs). The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore the following: 1) the fundamental biology underlying genetic and phenotypic drug-resistance in TB; 2) progress in expanding capacity in high burden settings to perform drug susceptibility testing; 3) identification of novel drug target; 4) innovative strategies for drug discovery; and 5) advances in developing multidrug regimens that will be effective against currently drug- resistant as well as drug-sensitive strains of M. tuberculosis. Investigators from outside the TB field will be included to provide new perspectives and stimulate fresh approaches for tackling this global public health priority. PUBLIC HEALTH RELEVANCE: In 2009 there were 9.4 million new cases of active tuberculosis (TB) and 1.7 million deaths due to TB. According to the World Health Organization, one-third of the world's population is currently infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis, and five to ten percent of those infected will develop active TB at some point in their lives. The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore gaps in our knowledge and current capacity that are key to successfully meeting the challenge of overcoming TB drug resistance globally.

产品说明： 本申请请求支持由Ann M. Ginsberg和John D.麦金尼，将于2012年5月13日至18日在乌干达坎帕拉举行。根据世界卫生组织的数据，在一些次国家区域，超过25%的新结核病病例是耐多药结核病，截至2010年3月，58个国家报告了广泛耐药结核病（对主要类别的一线和二线药物都具有耐药性的结核病）。关于结核病耐药性和持久性的基石研讨会会议旨在汇集来自不同背景的基础和临床研究人员以及公共卫生专家，探讨以下问题：1）结核病遗传和表型耐药性的基础生物学; 2）在高负担环境中扩大进行药物敏感性测试的能力方面取得的进展; 3）确定新的药物靶点; 4）药物发现的创新策略;和5）开发多药治疗方案的进展，所述多药治疗方案将有效地对抗目前耐药以及药物敏感的M.结核来自结核病领域以外的研究人员将参与进来，为解决这一全球公共卫生优先事项提供新的视角和激励新的方法。 公共卫生相关性： 2009年，有940万新的活动性结核病病例，170万人死于结核病。根据世界卫生组织的数据，目前世界上三分之一的人口感染了结核分枝杆菌，这种细菌导致结核病，其中5%到10%的感染者将在生命的某个时候发展为活动性结核病。关于结核病耐药性和持久性的Keystone专题讨论会旨在汇集来自不同背景的基础和临床研究人员以及公共卫生专家，探讨我们的知识和现有能力方面的差距，这些差距是成功应对全球结核病耐药性挑战的关键。